Pioneering new therapies through clinical trials to meet the unmet needs of patients with chronic inflammatory skin diseases.
Clinical trials investigating novel experimental therapies for chronic inflammatory skin diseases such as atopic dermatitis (AD) and prurigo nodularis (PN) constitute a core component of our research activities. Although the therapeutic landscape for AD has expanded in recent years with the introduction of systemic agents such as biologics and JAK inhibitors, a substantial unmet clinical need and persistent disease burden remain. This gap is even more pronounced in PN, for which dupilumab currently represents the only approved advanced systemic treatment.
To address these therapeutic shortcomings, we actively engage in industry-sponsored phase II and III clinical trials aimed at evaluating the efficacy and safety of emerging therapies with innovative mechanisms of action. These investigational agents, which target chronic type 2-driven inflammation, include novel approaches such as modulation of the OX40 pathway and inhibition of specific interleukins that are not yet commercially available. Below, you can find an overview of our current trials.
Dit is een fase 2 studie en de duur is 160 weken.
Open voor inclusie voor adolescenten van 12 -17 jaar met een lichaamsgewicht van <40kg.
Atlantis: A Phase 2, 160-Week, Open-Label multinational, multicenter study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous amlitelimab in participants aged 12 – 17 years with moderate to severe atopic dermatitis and a bodyweigt of < 40 kg. Open for inclusion.
Planet: A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects with Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies. Open for inclusion.
Rocket-Ascend: A Phase 3, 104-Week, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects with Moderate-to-severe Atopic Dermatitis (AD)
Trapeds 2: A Phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (age 4 to <12 years) with moderate-to-severe atopic dermatitis. Open for inclusion.
Pedistad: Prospective, observational, longitudinal study in pediatric patients with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable.